Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIANER: Neratinib Diarrhea Prophylaxis Strategies
NCT05252988Phase 2Active, not recruiting
- Sponsor
- GEICAM
- Start
- Aug 2022
- Primary completion
- Oct 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of neratinib in breast cancer (3 arms), sponsored by GEICAM. Primary endpoint: Incidence of neratinib discontinuations due to diarrhoea. Started Aug 2022; status: active, not recruiting.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05252988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252988.